Evidence map›Paper›PMID 38381151›Full record

SynthesisEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery2024

Global frequency and distribution of head and neck sarcomas in adulthood: a systematic review.

Giuditta Mannelli, Sara Bassani, Ginevra Cosi, Matteo Fermi, Luca Gazzini, Carlotta Liberale, Luca Mazzetti, Giampiero Parrinello, Alberto Maria Saibene, Gabriele Molteni and 1 more

Abstract readSystematic Review
PubMed Publisher
In one paragraph

Synthesis in European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 3 countries.

Giuditta MannelliYoung Confederation of European ORL-HNS, Y-CEORL-HNS, Vienna, Austria.
Sara BassaniYoung Confederation of European ORL-HNS, Y-CEORL-HNS, Vienna, Austria.
Ginevra CosiYoung Confederation of European ORL-HNS, Y-CEORL-HNS, Vienna, Austria.
Matteo FermiYoung Confederation of European ORL-HNS, Y-CEORL-HNS, Vienna, Austria.
Luca GazziniYoung Confederation of European ORL-HNS, Y-CEORL-HNS, Vienna, Austria.
Carlotta LiberaleYoung Confederation of European ORL-HNS, Y-CEORL-HNS, Vienna, Austria.
Luca MazzettiYoung Confederation of European ORL-HNS, Y-CEORL-HNS, Vienna, Austria.
Giampiero ParrinelloYoung Confederation of European ORL-HNS, Y-CEORL-HNS, Vienna, Austria.
Alberto Maria SaibeneYoung Confederation of European ORL-HNS, Y-CEORL-HNS, Vienna, Austria.
Gabriele MolteniYoung Confederation of European ORL-HNS, Y-CEORL-HNS, Vienna, Austria.
Lara Valentina CominiYoung Confederation of European ORL-HNS, Y-CEORL-HNS, Vienna, Austria. lv.comini@gmail.com.ORCID http://orcid.org/0000-0002-3639-1504
University of Florence · ITAzienda USL di Bologna · ITUniversity of Verona · ITAOL (United States) · USCentral European University · ATMartin University · USOspedale di Bolzano · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeHead and neck sarcomas (HNS) constitute a rare and heterogeneous cancer entity. Management remains a challenge due their rarity and different biological behaviour among tens of subtypes. This systematic review aimed to describe HNS global frequency and distribution in adulthood.

methodsA systematic review was performed using PICOTS search strategies for qualitative question and it was written in accordance with PRISMA 2020 Statement. 70,653 publications were identified, and 15 variables were evaluated for a total of 2428 patients.

resultsWe identified 47 studies from 21 different countries from 5 different continents. Most of studies (83.3%) were performed in single institutions and America and Asia overruled for number of papers included (21 and 10, respectivelly). Osteosarcoma was more frequent, followed by chondrosarcoma, angiosarcoma and malignant fibrous histiocytoma. Early stage accounted for almost 80% of cases; advanced stage prevailed in developing countries. 1783 patients (90.1%) underwent surgery and 780 (39.4%) had adjuvant therapy. 50.8% of patients experienced tumour recurrence and the lowest mortality rate was reported in Europe (29.9%).

conclusionsHNS holds a relative poor prognosis possibly explained by the heterogeneity of the disease. Treatment of HNS has shown to be highly diverse among different countries, underlining the importance of uniformed treatment guidelines to achieve better patient management and to improve survival outcomes.

Indexed as

Global HealthHead and Neck NeoplasmsSarcomaAdultHumansCancerDistributionHead and neckPrognosisSarcoma

Identifiers

PMID38381151
OpenAlexW4392018828

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.